Eslicarbazepine acetate in post‐stroke epilepsy: Clinical practice evidence from Euro‐Esli.

Objectives: To assess the effectiveness and safety/tolerability of eslicarbazepine acetate (ESL) in patients included in the Euro‐Esli study who had focal seizures associated with post‐stroke epilepsy (PSE). Materials and Methods: Euro‐Esli was a pooled analysis of 14 European clinical practice studies. Effectiveness assessments (evaluated after 3, 6 and 12 months of ESL treatment and at final follow‐up ["last visit"]) included rates of response (≥50% seizure frequency reduction), seizure freedom (no seizures since at least the prior visit) and retention. Safety/tolerability was assessed throughout ESL treatment by evaluating adverse events (AEs) and discontinuation due to AEs. A post hoc analysis was conducted of patients with PSE versus patients without PSE ("non‐PSE"). Results: Of 1656 patients included in the analysis, 76 (4.6%) had PSE and 1580 (95.4%) had non‐PSE. Compared with non‐PSE patients, PSE patients were significantly older, had significantly shorter epilepsy duration, significantly lower total baseline seizure frequency, and were treated with significantly fewer prior and concomitant antiepileptic drugs (P <.001 for all). At the last visit, the responder rate was significantly higher in PSE versus non‐PSE patients (72.9% vs 60.6%; P =.040), as was the seizure freedom rate (48.6% vs 31.7%; P =.003). After 12 months, retention was significantly higher in PSE versus non‐PSE patients (87.8% vs 77.4%; P =.035). The incidence of AEs was similar for PSE versus non‐PSE patients (36.0% vs 35.8%; P =.966). Conclusions: These findings suggest that ESL may be an effective and well‐tolerated treatment option for patients with focal seizures due to PSE. [ABSTRACT FROM AUTHOR]